Table 1.
Baseline characteristics of study participants according to quartiles of prediagnostic plasma adiponectin
| Quartiles of plasma adiponectin | ||||
|---|---|---|---|---|
| Characteristic | 1 (n=196) | 2 (n=134) | 3 (n=151) | 4 (n=140) |
| Age at diagnosis, y, mean (SD) | 68.8 (8.7) | 69.6 (7.7) | 70.8 (8.6) | 71.3 (7.8) |
| Body mass index, kg/m2, mean (SD) | 27.3 (4.4) | 26.8 (4.5) | 25.4 (3.6) | 24.3 (3.6) |
| Gender | ||||
| Males, % | 46 | 46 | 50 | 34 |
| Females, % | 54 | 54 | 50 | 66 |
| Race | ||||
| White, % | 94 | 96 | 94 | 99 |
| Other, % | 6 | 4 | 6 | 1 |
| Smoking status | ||||
| Current or past, % | 59 | 51 | 58 | 57 |
| Never, % | 41 | 49 | 42 | 43 |
| Physical activity, METs, mean (SD) | 20.3 (18.3) | 22.7 (22.8) | 24.4 (25.9) | 24.4 (25.6) |
| Regular use of aspirin or NSAIDs, ≥2 tablets/week, % | 51 | 37 | 50 | 49 |
| Year of CRC diagnosis, y, mean (SD) | 2000 (4) | 2000 (5) | 1999 (4) | 1999 (5) |
| Tumor location, % | ||||
| Colon | 91 | 85 | 88 | 89 |
| Rectum | 9 | 15 | 12 | 11 |
| Stage of Disease, % | ||||
| I | 27 | 30 | 30 | 24 |
| II | 24 | 21 | 21 | 25 |
| III | 20 | 19 | 17 | 24 |
| IV | 12 | 15 | 13 | 16 |
| Other/unknown | 17 | 16 | 19 | 12 |
| Grade of differentiation, % | ||||
| Well | 6 | 15 | 17 | 6 |
| Moderate | 62 | 47 | 51 | 60 |
| Poor/undifferentiated | 13 | 16 | 11 | 18 |
| Unknown | 19 | 22 | 22 | 16 |
METs = metabolic equivalent task score hours per week; NSAIDs = nonsteroidal anti-inflammatory drugs; SD = standard deviation; CRC = colorectal cancer